Alk-Abello AS (CHIX:ALKBC) Long-Term Debt: kr147 Mil (As of Mar. 2026)


CHIX:ALKBC Alk-Abello AS CHIX:ALKBC
93 GF Score
Price kr256.30
GF Value kr207.52
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alk-Abello AS Long-Term Debt?

Alk-Abello AS CHIX:ALKBC 93 Long-Term Debt is kr147 Mil as of Mar. 2026. GuruFocus rates CHIX:ALKBC with a GF Score™ of 93/100 and a GF Value™ of kr207.52 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Alk-Abello AS's Long-Term Debt for the quarter that ended in Mar. 2026 was kr147 Mil.

Alk-Abello AS's quarterly Long-Term Debt declined from Sep. 2025 (kr155 Mil) to Dec. 2025 (kr151 Mil) and declined from Dec. 2025 (kr151 Mil) to Mar. 2026 (kr147 Mil).

Alk-Abello AS's annual Long-Term Debt declined from Dec. 2023 (kr184 Mil) to Dec. 2024 (kr166 Mil) and declined from Dec. 2024 (kr166 Mil) to Dec. 2025 (kr151 Mil).

Alk-Abello AS  (CHIX:ALKBc) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Alk-Abello AS Long-Term Debt Related Terms

Alk-Abello AS Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Alk-Abello AS's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS Long-Term Debt Chart

Alk-Abello AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.00 203.00 184.00 166.00 151.00

Alk-Abello AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 161.00 159.00 155.00 151.00 147.00
CHIX:ALKBC
93GF Score
Alk-Abello AS CHIX:ALKBC
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of kr147 Mil mean?
Alk-Abello AS (CHIX:ALKBC) has a Long-Term Debt of kr147 Mil as of Mar. 2026.
Is Alk-Abello AS's Long-Term Debt too high?
Alk-Abello AS's current Long-Term Debt is kr147 Mil. Overall, Alk-Abello AS has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Long-Term Debt compare to VRTX and REGN?
Alk-Abello AS's Long-Term Debt of kr147 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Alk-Abello AS's current Long-Term Debt is kr147 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.52, compared to a current price of kr256.30 — trading 23.5% above its estimated fair value. The current Long-Term Debt is kr147 Mil. Alk-Abello AS's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Long-Term Debt is kr147 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of kr256.30 is trading 23.5% above its estimated GF Value™ of kr207.52. GuruFocus considers Alk-Abello AS to be Modestly Overvalued.

Key valuation signals for CHIX:ALKBC:

  • Long-Term Debt: kr147 Mil
  • GF Value™: kr207.52 vs. price of kr256.30 (23.5% above fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
93GF Score

Get the complete analysis for CHIX:ALKBC

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr256.30
Price
kr207.52
GF Value